BB Biotech AG Maintains 4.19M Share Stake in Esperion Therapeutics

TL;DR

**BB Biotech AG still holds over 4 million shares of Esperion, signaling continued institutional interest.**

AI Summary

BB Biotech AG, a Swiss investment company, has filed an amendment to its Schedule 13G, indicating a change in its beneficial ownership of Esperion Therapeutics, Inc. common stock as of December 31, 2023. The filing shows BB Biotech AG now holds shared voting and dispositive power over 4,194,064 shares, representing a significant stake in the pharmaceutical company. This matters to investors because a large institutional holder like BB Biotech AG maintaining a substantial position can signal confidence in Esperion's future, potentially influencing stock price and investor sentiment.

Why It Matters

This filing shows a major institutional investor, BB Biotech AG, continues to hold a significant stake in Esperion Therapeutics, which can be seen as a vote of confidence in the company's prospects.

Risk Assessment

Risk Level: low — This filing is an update on an existing institutional holding, not a new position or a significant divestment, indicating low immediate risk.

Analyst Insight

Investors should note that a major institutional holder, BB Biotech AG, is maintaining its position in Esperion Therapeutics, which could be a positive signal, but further research into Esperion's fundamentals and BB Biotech's investment strategy is warranted.

Key Numbers

• 4,194,064 — Shares Beneficially Owned (Represents the number of Esperion Therapeutics common shares over which BB Biotech AG has shared voting and dispositive power as of December 31, 2023.)

Key Players & Entities

• BB Biotech AG (company) — the reporting person and institutional investor
• Esperion Therapeutics, Inc. (company) — the subject company whose stock is being reported
• Switzerland (person) — place of organization for BB Biotech AG
• 4,194,064 (dollar_amount) — number of shares beneficially owned with shared voting and dispositive power
• December 31, 2023 (person) — date of event requiring the filing

Forward-Looking Statements

• BB Biotech AG will maintain its significant stake in Esperion Therapeutics for the foreseeable future. (BB Biotech AG) — medium confidence, target: December 31, 2024

FAQ

Key Financial Figures

• $0.001 — s of Securities Common Stock, par value $0.001 per share 2(e) CUSIP Number 29664W10

Filing Documents

• d155477dsc13ga.htm (SC 13G/A) — 50KB
• 0001193125-24-014167.txt ( ) — 52KB

Ownership

Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 4,194,064 (b) Percent of class: 3.7% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote 0 (ii) Shared power to vote or to direct the vote 4,194,064 (iii) Sole power to dispose or to direct the disposition of 0 (iv) Shared power to dispose or to direct the disposition of 4,194,064 Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person. This statement is filed jointly by BB Biotech and Biotech Target, Biotech Target is a wholly-owned subsidiary of BB Biotech. 4

Certification

Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURES

SIGNATURES After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. BB Biotech AG Date: January 24, 2024 By: /s/ Martin Gubler Signatory Authority Name: Martin Gubler Title: Signatory Authority Date: January 24, 2024 By: /s/ Ivo Betschart Signatory Authority Name: Ivo Betschart Title: Signatory Authority Biotech Target N.V. Date: January 24, 2024 By: /s/ Jan Bootsma Signatory Authority Name: Jan Bootsma Title: Signatory Authority Date: January 24, 2024 By: /s/ Hugo van Neutegem Signatory Authority Name: Hugo van Neutegem Title: Signatory Authority 5 Exhibit Index Exhibit A: Agreement by and between BB Biotech AG and Biotech Target N.V. with respect to the filing of this disclosure statement.* * Previously filed as an exhibit to BB Biotech AG and Biotech Target N.V.s Schedule 13G filed with the Securities and Exchange Commission on September 27, 2016. 6

View Full Filing

View this SC 13G/A filing on SEC EDGAR